Effect of systemic immunosuppression on coronary in-stent intimal hyperplasia in renal transplant patients

American Journal of Cardiology

Volumn 91, Issue 11, 2003, Pages 1363-1365

  Arruda, J Airton ^b   Costa, Marco A ^b   Brito Jr , Fábio S ^b   Tedesco, Hélio ^b   Barbosa, Adriano H P ^b   Ribeiro, Érika P ^b   Pestana, Jose O M ^b   Lima, Valter C ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TICLOPIDINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; IMAGING SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INTRAVASCULAR ULTRASOUND; KIDNEY ALLOGRAFT; KIDNEY DISEASE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; PRIORITY JOURNAL; RESTENOSIS; RIGHT CORONARY ARTERY; SURGICAL PATIENT; TREATMENT OUTCOME;

EID: 0038626400     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00333-3     Document Type: Article

References (19)

1. Jonasson L., Holm J., Hansson G.K. Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury. Proc Natl Acad Sci USA. 85:1988;2303-2306.
2. Voisard R., Seitzer U., Baur R., Dartsch P.C., Osterhues H., Hoher M., Hombach V. A prescreening system for potential antiproliferative agents implications for local treatment strategies of postangioplasty restenosis . Int J Cardiol. 51:1995;15-28.
3. Poon M., Marx S.O., Gallo R., Badimon J.J., Taubman M.B., Marks A.R. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 98:1996;2277-2283.
4. Burke S.E., Lubbers N.L., Chen Y.W., Hsieh G.C., Mollison K.W., Luly J.R., Wegner C.D. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin. J Cardiovasc Phamacol. 33:1999;829-835.
5. Mehran R., Mintz G.S., Hong M.K., Tio F.O., Bramwell O., Brahimi A., Kent K.M., Pichard A.D., Satler L.F., Popma J.J., Leon M.B. Validation of the in vivo intravascular ultrasound measurement of in-stent neointimal hyperplasia volumes. J Am Coll Cardiol. 32:1998;794-799.
6. von Birgelen C., Di Mario C., Li W., Schuurbiers J.C., Slager C.J., de Feyter P.J., Roelandt J.R., Serruys P.W. Morphometric analysis in three-dimensional intracoronary ultrasound an in vitro and in vivo study performed with a novel system for the contour detection of lumen and plaque . Am Heart J. 132:1996;516-527.
7. Kasiske B.L., Chakkera H.A., Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol. 11:2000;1735-1743.
8. Abizaid A., Kornowski R., Mintz G.S., Hong M.K., Abizaid A.S., Mehran R., Pichard A.D., Kent K.M., Satler L.F., Wu H., Popma J.J., Leon M.B. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol. 32:1998;584-589.
9. Ellis S.G., Effron M.B., Gold H.K., Leon M.B., Popma J.J., Serruys P.W. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators. Circulation. 100:1999;799-806.
10. Lincoff A.M., Califf R.M., Moliterno D.J., Ellis S.G., Ducas J., Kramer J.H., Kleiman N.S., Cohen E.A., Booth J.E., Sapp S.K., Cabot C.F., Topol E.J. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med. 341:1999;319-327.
11. Stone G.W., Rutherford B.D., McConahay D.R., Johnson W.L., Giorgi L.V., Ligon R.W., Hartzler G.O. A randomized trial of corticosteroides for the prevention of restenosis in 102 patients undergoing repeat coronary angioplasty. Cathet Cardiovasc Diagn. 18:1989;227-231.
12. Lee C.W., Chae J.K., Lim H.Y., Hong M.K., Kim J.J., Park S.W., Park S.J. Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation. Am Heart J. 138:1999;60-63.
13. Andersen H.O., Hansen B.F., Holm P., Stender S., Nordestgaard B.G. Effect of cyclosporine on arterial balloon injury lesions in cholesterol-clamped rabbits T lymphocyte-mediated immune responses not involved in balloon injury-induced neointimal proliferation . Arterioscler Thromb Vasc Biol. 19:1999;1687-1694.
14. Costa M.A., Sabate M., Kay I.P., de Feyter P.J., Kozuma K., Serrano P., de Valk V., Albertal M., Ligthart J.M., Disco C., Foley D.P., Serruys P.W. Three-dimensional intravascular ultrasonic volumetric quantification of stent recoil and neointimal formation of two new generation tubular stents. Am J Cardiol. 85:2000;135-139.
15. Sousa J.E., Costa M.A., Abizaid A.C., Rensing B.J., Abizaid A.S., Tanajura L.F., Kozuma K., Van Langenhove G., Sousa A.G., Falotico R., et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents one-year angiographic and intravascular ultrasound follow-up . Circulation. 104:2001;2007-2011.
16. Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M., Colombo A., Schuler G., Barragan P., Guagliumi G., Molnar F., Falotico R. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 346:2002;1773-1780.
17. Lefkovits J., Topol E.J. Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention. Prog Cardiovasc Dis. 40:1997;141-158.
18. Andoh T.F., Burdmann E.A., Bennett W.M. Nephrotoxicity of immunosuppressive drugs experimental and clinical observations . Semin Nephrol. 17:1997;34-45.
19. Farb A., John M., Acampado E., Kolodgie F.D., Prescott M.F., Virmani R. Oral everolimus inhibits in-stent neointimal growth. Circulation. 106:2002;2379-2384.